首页> 美国卫生研究院文献>BMC Nephrology >Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations
【2h】

Identification of compound heterozygous patients with primary hyperoxaluria type 1: clinical evaluations and in silico investigations

机译:原发性高草酸尿症类型的复合杂合患者的鉴定1:临床评估和计算机调查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPrimary hyperoxaluria type 1 (PH1) is an autosomal recessive inherited disorder of glyoxylate metabolism in which excessive oxalates are formed by the liver and excreted by the kidneys. Calcium oxalate crystallizes in the urine, leading to urolithiasis, nephrocalcinosis, and consequent renal failure if treatment is not initiated promptly. Mutations in the AGXT gene which encodes the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase are responsible of PH1. In the present work, we aimed to analyze AGXT gene and in silico investigations performed in four patients with PH1 among two non consanguineous families.
机译:背景1型原发性高草酸尿症(PH1)是乙醛酸代谢的常染色体隐性遗传性疾病,其中过量的草酸盐由肝脏形成,并由肾脏排泄。如果不及时开始治疗,草酸钙会在尿液中结晶,导致尿路结石,肾钙化和随后的肾衰竭。编码肝脏过氧化物酶体酶丙氨酸:乙醛酸氨基转移酶的AGXT基因突变引起PH1。在当前的工作中,我们旨在分析AGXT基因和在两个非近亲家庭中的四名PH1患者中进行的计算机分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号